[Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].
作者信息
Zhao F, Cheng L L, Zheng Z, Zhang M C, Cheng S, Xu P P, Wang L, Zhao W L
机构信息
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China Zhao Fang is working at the Hematology Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology, Urumqi 830054, China.
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):513-517. doi: 10.3760/cma.j.issn.0253-2727.2022.06.012.
Abstract
摘要
相似文献
1
[Analysis of clinical factors of bendamustine combined with rituximab in the treatment of recurrent follicular lymphoma].苯达莫司汀联合利妥昔单抗治疗复发滤泡性淋巴瘤的临床因素分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):513-517. doi: 10.3760/cma.j.issn.0253-2727.2022.06.012.
2
Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.苯达莫司汀联合利妥昔单抗作为西班牙滤泡性淋巴瘤患者一线治疗方案的成本效益分析
Appl Health Econ Health Policy. 2016 Aug;14(4):465-477. doi: 10.1007/s40258-016-0243-4.
3
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.一线免疫化疗后复发或难治性滤泡淋巴瘤患者采用利妥昔单抗、苯达莫司汀、米托蒽醌和地塞米松应答适应性治疗继以利妥昔单抗维持治疗的 RBMDGELTAMO08 期 II 临床试验结果。
Cancer Med. 2019 Nov;8(16):6955-6966. doi: 10.1002/cam4.2555. Epub 2019 Oct 1.
4
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.两例滤泡性淋巴瘤患者在接受苯达莫司汀和奥滨尤妥珠单抗或利妥昔单抗治疗后出现持续性 SARS-CoV-2 感染和多次临床复发。
Infection. 2023 Oct;51(5):1577-1581. doi: 10.1007/s15010-023-02039-2. Epub 2023 Apr 19.
5
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.抗 CD20 抗体和苯达莫司汀可减弱 B 细胞非霍奇金淋巴瘤患者对 COVID-19 疫苗的体液免疫反应。
Ann Hematol. 2023 Jun;102(6):1421-1431. doi: 10.1007/s00277-023-05204-7. Epub 2023 Apr 12.
6
Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.苯达莫司汀与利妥昔单抗联合治疗副肿瘤性天疱疮取得成功。
Ann Hematol. 2017 Jul;96(7):1221-1222. doi: 10.1007/s00277-017-3008-8. Epub 2017 Apr 26.
7
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.在美国，对于接受含利妥昔单抗方案治疗后复发或难治的滤泡性淋巴瘤患者，奥妥珠单抗联合苯达莫司汀继以奥妥珠单抗单药治疗的成本效益分析
J Med Econ. 2018 Oct;21(10):960-967. doi: 10.1080/13696998.2018.1489254. Epub 2018 Jul 6.
8
Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.苯达莫司汀暴露对滤泡性淋巴瘤患者接受苯达莫司汀与利妥昔单抗联合治疗后淋巴细胞减少风险的临床影响：一项单机构回顾性研究
Ann Hematol. 2022 Jan;101(1):209-211. doi: 10.1007/s00277-020-04388-6. Epub 2021 Jan 3.
9
[Standard treatment and future perspectives for follicular lymphoma].[滤泡性淋巴瘤的标准治疗及未来展望]
Rinsho Ketsueki. 2022;63(9):1135-1144. doi: 10.11406/rinketsu.63.1135.
10
The optimal management of follicular lymphoma: an evolving field.滤泡性淋巴瘤的最佳治疗策略：一个不断发展的领域。
Drugs. 2013 Sep;73(13):1395-403. doi: 10.1007/s40265-013-0092-5.
本文引用的文献
1
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发滤泡性淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Mar;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008. Epub 2020 Nov 26.
2
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups.现代滤泡性淋巴瘤：生存、治疗结果和高危亚组的识别。
Blood Cancer J. 2020 Jul 17;10(7):74. doi: 10.1038/s41408-020-00340-z.
3
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.苯达莫司汀与利妥昔单抗联合替西罗莫司（BeRT）治疗复发套细胞淋巴瘤和滤泡性淋巴瘤的I/II期试验最终结果
Hemasphere. 2020 Jun 8;4(3):e398. doi: 10.1097/HS9.0000000000000398. eCollection 2020 Jun.
4
First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.一线 R-CVP 与 R-CHOP 诱导免疫化疗联合利妥昔单抗维持治疗惰性淋巴瘤的多中心 III 期随机研究。由波兰淋巴瘤研究小组（PLRG4）进行。
Br J Haematol. 2020 Mar;188(6):898-906. doi: 10.1111/bjh.16264. Epub 2019 Dec 2.
5
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.生发中心 B 细胞中 CREBBP 和 EP300 乙酰转移酶的独特和共有表观遗传程序揭示了淋巴瘤中可靶向的依赖性。
Immunity. 2019 Sep 17;51(3):535-547.e9. doi: 10.1016/j.immuni.2019.08.006. Epub 2019 Sep 10.
6
m7FLIPI and targeted sequencing in high-risk follicular lymphoma.m7FLIPI 与高危滤泡性淋巴瘤的靶向测序。
Hematol Oncol. 2019 Dec;37(5):564-568. doi: 10.1002/hon.2674. Epub 2019 Oct 25.
7
M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.M7-FLIPI 不适用于一线无利妥昔单抗化疗的滤泡性淋巴瘤患者的预后评估。
Br J Haematol. 2020 Jan;188(2):259-267. doi: 10.1111/bjh.16159. Epub 2019 Aug 18.
8
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.滤泡性淋巴瘤：最新和新兴的治疗方法、治疗策略和未满足的需求。
Oncologist. 2019 Nov;24(11):e1236-e1250. doi: 10.1634/theoncologist.2019-0138. Epub 2019 Jul 25.
9
Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study.苯达莫司汀-120 联合利妥昔单抗治疗复发或难治性滤泡性淋巴瘤：一项多中心 II 期研究。
Ann Hematol. 2019 Sep;98(9):2131-2138. doi: 10.1007/s00277-019-03750-7. Epub 2019 Jul 8.
10
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.苯达莫司汀联合利妥昔单抗与 R-CHOP 或 R-CVP 一线治疗惰性非霍奇金淋巴瘤或套细胞淋巴瘤患者：BRIGHT 5 年随访研究结果。
J Clin Oncol. 2019 Apr 20;37(12):984-991. doi: 10.1200/JCO.18.00605. Epub 2019 Feb 27.
Zotero 插件